Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody.

ABSTRACT:

Background

Recent studies have reported that similar to other IgG4 autoimmune diseases, such as muscle-specific kinase antibody-associated myasthenia gravis, most anti-neurofascin-155 (anti-NF155) nodopathies respond well to rituximab treatment, regardless of the dosage. However, there are still a few patients for which rituximab is ineffective for unknown reasons. Currently, there are no studies on the mechanism of ineffective treatment with rituximab.

Methods

A 33-year-old Chinese man presenting with numbness, tremor, and muscle weakness for 4 years was recruited for this study. Anti-NF155 antibodies were identified by cell-based assay and confirmed by immunofluorescence assay on teased fibers. The anti-NF155 immunoglobulin (IgG) subclasses were also detected by immunofluo

SUBMITTER: Bai Y 

PROVIDER: S-EPMC10086195 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature